AKBA CIK: 1517022

Akebia Therapeutics, Inc.

  • United States
  • Healthcare
  • Pharma
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
−253
FY22:
−73.2
FY23:
−23.4
FY24:
−40.7
FY25:
68.0
Change from FY21 to FY25
millions USD
FY21:
39.9
FY22:
−0.11
FY23:
0
FY24:
−0.03
FY25:
−7.93
Change from FY21 to FY25
millions USD
FY21:
134
FY22:
14.6
FY23:
−25.2
FY24:
49.7
FY25:
72.9
millions USD
FY21:
−79.3
FY22:
−58.7
FY23:
−48.6
FY24:
8.97
FY25:
133
(positive)
Change from FY21 to FY25
millions USD
FY21:
−253
FY22:
−73.3
FY23:
−23.4
FY24:
−40.7
FY25:
67.7

All amounts in millions USD Data source:SEC EDGAR